Alenazi Shahad Farhan, Almutairi Ghada Mahaya, Sheikho Maha Ahmed, Al Alshehri Mona Ahmed, Alaskar Batool Mousa, Al Sayyari Abdullah Ahmed
From the College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
Exp Clin Transplant. 2019 Dec;17(6):714-719. doi: 10.6002/ect.2018.0396. Epub 2019 May 14.
We investigated the impact of nonimmuno-logic factors on patient and graft survival after deceased-donor kidney transplant.
All deceased-donor kidney transplants performed between January 2004 and December 2015 were included in our analyses. We used the independent t test to calculate significant differences between means above and below medians of various parameters.
All study patients (N = 205; 58.7% males) received antithymocyte globulin as induction therapy and standard maintenance therapy. Patients were free from infection, malignancy, and cardiac, liver, and pulmonary system abnormalities. Most patients (89.2%) were recipients of a first graft. Median patient age, weight, and cold ischemia time were 38 years, 65 kg, and 15 hours, respectively. Delayed graft function, diabetes mellitus, and hypertension occurred in 19.1%, 43.4%, and 77.9% of patients, respectively. The 1- and 5-year graft survival rates were 95% and 73.8%. Graft survival was not affected by donor or recipient sex or recipient diabetes or hypertension. However, graft survival was longer in patients who received no graft biopsy (8.2 vs 6.9 y; P = .027) and in those who had diagnosis of calcineurin inhibitor nephrotoxicity versus antibody-mediated rejection after biopsy (8.19 vs 3.66 y; P = .0047). Longer survival was shown with donors who had traumatic death versus cerebro-vascular accident (5.9 vs 5.3 y; P = .029) and donors below the 50th percentile in age (8.23 and 7.14 y; P = .0026) but less with donors who had terminal acute kidney injury (6.97 vs 8.16 y; P = .0062). We found a negative correlation between graft survival and donor age (P = .01) and 1-year serum creatinine (P = .01).
Donor age, cause of brain death, and acute kidney injury affected graft survival in our study cohort but not donor or recipient sex or posttransplant or donor blood pressure.
我们研究了非免疫因素对尸体供肾移植术后患者及移植物存活的影响。
我们的分析纳入了2004年1月至2015年12月期间进行的所有尸体供肾移植。我们使用独立t检验来计算各种参数中位数上下均值之间的显著差异。
所有研究患者(N = 205;58.7%为男性)均接受抗胸腺细胞球蛋白作为诱导治疗及标准维持治疗。患者无感染、恶性肿瘤以及心脏、肝脏和肺部系统异常。大多数患者(89.2%)为首次接受移植物。患者年龄中位数、体重和冷缺血时间分别为38岁、65千克和15小时。移植肾功能延迟、糖尿病和高血压分别发生在19.1%、43.4%和77.9%的患者中。1年和5年移植物存活率分别为95%和73.8%。移植物存活不受供者或受者性别、受者糖尿病或高血压的影响。然而,未进行移植肾活检的患者移植物存活时间更长(8.2年对6.9年;P = 0.027),活检后诊断为钙调神经磷酸酶抑制剂肾毒性而非抗体介导排斥反应的患者移植物存活时间更长(8.19年对3.66年;P = 0.0047)。创伤性死亡供者的移植物存活时间长于脑血管意外供者(5.9年对5.3年;P = 0.029),年龄低于第50百分位数的供者移植物存活时间长(8.23年和7.14年;P = 0.0026),但终末期急性肾损伤供者的移植物存活时间较短(6.97年对8.16年;P = 0.0062)。我们发现移植物存活与供者年龄(P = 0.01)和1年血清肌酐水平(P = 0.01)呈负相关。
在我们的研究队列中,供者年龄、脑死亡原因和急性肾损伤影响移植物存活,但不影响供者或受者性别、移植后或供者血压。